Diabetes PubMed

While regular monitoring of liver enzymes is still recommended and more long term data are desirable, current evidence from clinical trials and postmarketing experience in the US supports the conclusion that rosiglitazone and pioglitazone do not share the hepatotoxic profile of troglitazone.

Analysis of these cases and of the experimental troglitazone toxicity data points to mitochondrial toxicity as a central factor.

Thiazolidinediones are usually well tolerated; however, their use may be associated with several adverse effects. The first TZD, troglitazone, was withdrawn from the market owing to serious hepatotoxicity.

In conclusion, our study demonstrated for the first time that TGZS (Troglitazone sulfo-conjugated metabolite) has direct toxicity effect on human liver cells and may be partially responsible for the hepatotoxicity of TGZ (Troglitazone).